Detect gene mutations and diagnose blood cancer

1. Detection of single gene mutations that respond to targeted therapy

In recent years, the target gene mutation test to provide a suitable treatment regimen has become a priority in cancer treatment with outstanding advantages: Accurately attacking target cancer, improving efficiency clear treatment with the ability to repel tumors, prolong survival, reduce side effects…(1).

In particular, this type of test has clear guidelines and treatment regimens, with target drugs specified by FDA, Ministry of Health and hundreds of scientific publications. Some are covered by insurance (2).

Targeted drug efficacy figures after target gene testing compared with patients without mutations, patients with EGFR mutations have:

Drug response rate 68% vs 11%
Disease control rate 86% vs 42%
Time to cure 12 months compared to 3.4 months
Mean survival time 23.3 months vs 12.1 months (1)

2. Multigene mutations in solid tissue cancer

Cancer is a combination of many genetic mutations that lead to abnormalities in cell growth and functioning. The comprehensive assessment of gene mutations of one or more cancer types is one of the orientations to help clinicians come up with more accurate treatment regimens and improve cancer treatment efficiency. 3).

The human genome is about 20000 genes, more than 500 genes have been identified to be related to cancer (4).
A type of cancer is linked to a range of genes, for example: Non-small cell lung cancer involves the EGFR, ROS1, ALK genes (4).
A cancer gene is associated with many different types of cancer, for example, KRAS gene is associated with lung cancer, pancreatic cancer, rectal cancer…(5).

3. Diagnosis of blood cancer

Leukemia is a disease that occurs when cancerous cells multiply very quickly and if not treated promptly, they will accumulate in the bone marrow. This type of cancer has a fast and complicated progression, if not detected in time, can lead to death (6).

Determining blood cancer and finding the genetic cause helps to improve the accuracy of diagnosis, give the appropriate regimen and reduce the maximum cost for the patient.

Statistics in the US show:

Every 3 minutes someone is diagnosed with blood cancer
One person dies every 9 minutes
30% of pediatric cancer patients have leukemia (6)
In Viet Nam:

There were 10,913 new cases in 2018
2920 deaths
Total number of new cases of cancer ranks 5th among the most common cancers (7)
Different types of blood cancer have different treatment regimens and costs (8).

Biomedic's solution

1. Detection of single gene mutations that respond to targeted therapy

Biomedic provides a technology solution to detect mutations in common target genes that already have specific target drugs based on PCR technology on a large number of genes for solid tissue biopsies and especially with three common target genes on biopsies. liquid – a new direction in testing with the following advantages:

  • Certificate: CE-IVD
  • High quality
  • Various targeted genes: EGFR, KRAS, BRAF, NRAS, ROS1, EML4-ALK, PI3KA, ….
  • Liquid biopsy is less invasive, overcomes the weakness of wrong puncture, lacks the amount of biopsy sample…
  • Competitive price

2. Multigene mutations in solid tissue cancer

Biomedic provides NGS technology solution based on Illumina platform, comprehensive assessment of genes related to acquired cancer with only one test sample, with outstanding advantages:

  • Accurate result quality, nucleotide sensitivity
  • Detecting rare types of cancer, under the cancer group
  • High-speed, time-saving genome sequencing
  • Cost savings
  • Compatible with ultra-small, low-quality input samples

3. Diagnosis of blood cancer

Biomedic provides a comprehensive technology solution for genes and cells in blood cancer classification and identification and genetic cause analysis of blood cancers with the following advantages:

  • Kits and machines for blood cancer identification by Flow Cytometer achieve CE IVD certificate with outstanding advantages
  • Genome analysis kits are based on Illumina’s NGS platform with advantages in accuracy, sensitivity, high speed, time saving, cost…
  • With guidelines and reference results
  1. Neal I. L., J Thorac Oncol. 2013 Jul; 8(7): 823–859.
  3. Rick K.,, Int J Mol Sci. 2017 Feb; 18(2): 308.
  4. Masayuki N., Cancer Sci. 2019 Jan; 110(1): 6–15.
  5. Sylwia J., J Biomed Biotechnol. 2010: 150960
  6. National Foundation for Cancer Research – 7 facts you need to know about blood cancer
  7. Cancer in Vietnam Globocan 2018 WHO
  8. Jason Harris, Oncology Live 2019 Vol 20/No. 2.


TruSight Tumor 26

TruSight Tumor 26 Kit include reagents to prepare for Library preparation samples, sequencing 26 genes relating to solid cancer, variant of  soma in NGS – Next Generation Sequencing of Illumina

Next Generation Sequencing System – MiSeq

Model: MiSeq
Manufacturer: Illumina/USA
– The MiSeq System combines cluster generation, amplification, sequencing and data analysis on a single system
– The system is most widely used, with next-generation sequencing technology –  Sequencing by Synthesis – SBS